[go: up one dir, main page]

BG62759B1 - Средство и метод за лечение на автоимунни заболявания - Google Patents

Средство и метод за лечение на автоимунни заболявания Download PDF

Info

Publication number
BG62759B1
BG62759B1 BG100921A BG10092196A BG62759B1 BG 62759 B1 BG62759 B1 BG 62759B1 BG 100921 A BG100921 A BG 100921A BG 10092196 A BG10092196 A BG 10092196A BG 62759 B1 BG62759 B1 BG 62759B1
Authority
BG
Bulgaria
Prior art keywords
tbg
treatment
autoimmune diseases
glycoprotein
trophoblastic
Prior art date
Application number
BG100921A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG100921A (bg
Inventor
�Eoh�� Ka�Apaba
Original Assignee
Иван Николаевич Головистиков
Лeohид Язohobич Kaчapaba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иван Николаевич Головистиков, Лeohид Язohobич Kaчapaba filed Critical Иван Николаевич Головистиков
Publication of BG100921A publication Critical patent/BG100921A/xx
Publication of BG62759B1 publication Critical patent/BG62759B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BG100921A 1994-03-18 1996-10-18 Средство и метод за лечение на автоимунни заболявания BG62759B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU9494008169A RU2056852C1 (ru) 1994-03-18 1994-03-18 Средство для лечения аутоиммунных заболеваний с иммунодефицитом супрессоров и способ лечения аутоиммунных заболеваний
PCT/RU1995/000047 WO1995025531A1 (en) 1994-03-18 1995-03-16 Means for treating auto-immune diseases and method of treatment

Publications (2)

Publication Number Publication Date
BG100921A BG100921A (bg) 1997-12-30
BG62759B1 true BG62759B1 (bg) 2000-07-31

Family

ID=20153349

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100921A BG62759B1 (bg) 1994-03-18 1996-10-18 Средство и метод за лечение на автоимунни заболявания

Country Status (22)

Country Link
US (1) US6150326A (es)
EP (1) EP0790059B1 (es)
JP (1) JPH09510473A (es)
KR (1) KR100382252B1 (es)
CN (1) CN1146156A (es)
AT (1) ATE260111T1 (es)
AU (1) AU699896B2 (es)
BG (1) BG62759B1 (es)
CA (1) CA2185892A1 (es)
CZ (1) CZ285856B6 (es)
DE (2) DE69532611D1 (es)
ES (1) ES2107980T1 (es)
FI (1) FI963671A7 (es)
GE (1) GEP20012377B (es)
GR (1) GR980300023T1 (es)
HU (1) HUT75720A (es)
NO (1) NO963911L (es)
PL (1) PL179765B1 (es)
RU (1) RU2056852C1 (es)
SK (1) SK281948B6 (es)
UA (1) UA26939C2 (es)
WO (1) WO1995025531A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2120298C1 (ru) * 1995-11-28 1998-10-20 Товарищество с ограниченной ответственностью "Верта" Иммуностимулятор и препарат на его основе
FR2747041B1 (fr) * 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
GB0030729D0 (en) * 2000-12-16 2001-01-31 Univ Nottingham Substituted-4-Quinolones
US20050032725A1 (en) * 2002-10-09 2005-02-10 Toerrx, Inc. Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use
RU2303995C1 (ru) * 2006-04-28 2007-08-10 Халлар Абдумуслимович Алиханов Средство, обладающее иммунорегуляторным свойством и его применение для лечения аутоиммунных заболеваний

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1107772B (it) * 1977-08-22 1985-11-25 Cancer Res Inst Royal Procedimento per la produzione di complessi macromolecolari prodotto ottenuto e composizioni farmaceutiche che lo contengono come ingrediente attivo
JPS61186322A (ja) * 1985-02-13 1986-08-20 Nippon Univ 免疾調節剤
IT1188646B (it) * 1986-04-09 1988-01-20 Ellem Ind Farmaceutica Tripeptide ad attivita' immunostimolante
US4803072A (en) * 1986-09-10 1989-02-07 Smithkline Beckman Corporation Immunomodulation
FR2609632B1 (fr) * 1987-01-21 1991-03-29 Shelly Marc Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
US5169835A (en) * 1989-01-18 1992-12-08 Oklahoma Medical Research Foundation Pregancy specific proteins applications
FR2650183A1 (fr) * 1989-07-25 1991-02-01 Pasteur Institut Proteines immunostimulantes, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et application de ces produits a des fins therapeutiques et de diagnostic
US5118669A (en) * 1989-09-20 1992-06-02 Hitachi Chemical Co., Ltd. Peptides and intermediates therefor useful as antiallergic agents, vasodilators and immunoregulators
US5559097A (en) * 1990-01-12 1996-09-24 Idaho Research Foundation, Inc. Use of a pregnancy specific protein as an immunosuppressive
RU1836957C (ru) * 1990-03-25 1993-08-30 2-й Московский государственный медицинский институт им.Н.И.Пирогова Способ получени трофобластического бета @ -гликопротеина
GB2251186A (en) * 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease

Also Published As

Publication number Publication date
BG100921A (bg) 1997-12-30
ES2107980T1 (es) 1997-12-16
RU2056852C1 (ru) 1996-03-27
EP0790059A1 (en) 1997-08-20
CA2185892A1 (en) 1995-09-28
CZ274796A3 (en) 1997-06-11
FI963671L (fi) 1996-11-14
NO963911D0 (no) 1996-09-18
KR100382252B1 (ko) 2003-07-07
UA26939C2 (uk) 1999-12-29
NO963911L (no) 1996-11-08
EP0790059B1 (en) 2004-02-25
EP0790059A4 (en) 2000-11-02
HU9602558D0 (en) 1996-11-28
DE69532611D1 (de) 2004-04-01
DE790059T1 (de) 1998-03-12
PL179765B1 (pl) 2000-10-31
SK281948B6 (sk) 2001-09-11
WO1995025531A1 (en) 1995-09-28
JPH09510473A (ja) 1997-10-21
HUT75720A (en) 1997-05-28
CZ285856B6 (cs) 1999-11-17
ATE260111T1 (de) 2004-03-15
SK118796A3 (en) 1997-06-04
KR970701557A (ko) 1997-04-12
CN1146156A (zh) 1997-03-26
AU699896B2 (en) 1998-12-17
FI963671A7 (fi) 1996-11-14
AU2087495A (en) 1995-10-09
US6150326A (en) 2000-11-21
GEP20012377B (en) 2001-03-25
GR980300023T1 (en) 1998-04-30
PL316311A1 (en) 1997-01-06
FI963671A0 (fi) 1996-09-17

Similar Documents

Publication Publication Date Title
Stetson et al. Studies on the mechanism of the Shwartzman phenomenon: Evidence for the participation of polymorphonuclear leucocytes in the phenomenon
Ben Hamida et al. Severe childhood muscular dystrophy affecting both sexes and frequent in Tunisia
REWCASTLE et al. Vacuolar myopathy: clinical, histochemical, and microscopic study
Calvet et al. Interferon enhances the excitability of cultured neurones
Brettler et al. Factor VIII: C concentrate purified from plasma using monoclonal antibodies: human studies
Hazleman et al. Lymphocyte proliferation to artery antigen as a positive diagnostic test in polymyalgia rheumatica.
Barranco Mixed bullous disease
Klein et al. Thymoma and polymyositis: onset of myasthenia gravis after thymectomy: report of two cases
Eisen et al. Peripheral nerve function in long‐term therapy with diphenylhydantoin: A clinical and electrophysiologic correlation
WHITAKER et al. Skeletal muscle pseudohypertrophy in primary amyioidosis
BG62759B1 (bg) Средство и метод за лечение на автоимунни заболявания
SHUMAN Relapsing panniculitis (Weber-Christian disease): review of literature and report of a case including treatment with cortisone
Giaquinto et al. Reflex activity of extensor and flexor muscles following muscular afferent excitation during sleep and wakefulness
Sakuta et al. Diagnostic significance of membrane attack complex and vitronectin in childhood dermatomyositis
US2386725A (en) Therapeutic substance for measles
RU2095067C1 (ru) Способ стимуляции репаративных и трофических процессов в тканях организма
RU2124879C1 (ru) Способ комплексной рефлексотерапии
RU2152618C1 (ru) Способ определения лимфотоксичности лекарственных препаратов в реакции спонтанного е-розеткообразования
Glode et al. Effect of intravenous immune globulin on the coagulopathy of Kawasaki syndrome
SU1640653A1 (ru) Способ диагностики рассе нного склероза
KRAUSE et al. Treatment of metastatic meningococcic endophthalmitis: Report of a case
Tosca et al. Neuroendocrinological aspects of depression and symptomatological picture
SU1666116A1 (ru) Способ лечени невралгии тройничного нерва
Altınel Acoğlu et al. Familial Hypokalemic Periodic Paralysis with Mutation in a Voltage-Gated Calcium Channel
Smolin et al. High doses of subconjunctival corticosteroid and antibody-forming cells in the eye and draining lymph nodes